Use fundamental data analysis to check all available reported financial drivers of D N A to find out if markets are at this moment mispricing the company. We found twenty-four available fundamental indicators for D N A Biomedical Solutions Ltd which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all D N A fundamentals including its Cash and Equivalents, Number of Employees, Current Asset, as well as the relationship between Book Value Per Share and Total Asset . Use D N to protect against small markets fluctuations. The stock experiences normal downward trend and little activity. Check odds of D N to be traded at S23.66 in 30 days
D N Company Summary
D N competes with Israel Chemicals, NICE Ltd, and Elbit Systems. D.N.A Biomedical Solutions Ltd. develops and commercializes laser spectrometry-based trace detection systems in Israel. D.N.A Biomedical Solutions Ltd. was founded in 2004 and is based in Ramat Gan, Israel. D N operates under Biotechnology classification in Israel and traded on Tel Aviv Stock Exchange.
D N Retained Earnings vs Cash Flow from Operations
D N A Biomedical Solutions Ltd is rated # 4 in retained earnings category among related companies. It is rated # 4 in cash flow from operations category among related companies .
D N A Systematic Risk
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on D N A correlated with the market. If Beta is less than 0 D N generally moves in the opposite direction as compared to the market. If D N Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one D N A is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of D N is generally in the same direction as the market. If Beta > 1 D N moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
D N Financial Distress Probability
Chance of Financial Distress
D N A Biomedical Solutions Ltd has more than 88 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info